首页 > 最新文献

Journal of Investigational Allergology and Clinical Immunology最新文献

英文 中文
Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation. 在危及生命的哮喘加重期同情使用雷利珠单抗
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-23 Epub Date: 2023-06-21 DOI: 10.18176/jiaci.0920
P Granda, E Villamañán, S Heinz, D Laorden, D Romero, J M Añón, C Carpio, C Sobrino, V Collada, J Domínguez-Ortega, A Herrero, S Quirce, R Álvarez-Sala
{"title":"Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation.","authors":"P Granda, E Villamañán, S Heinz, D Laorden, D Romero, J M Añón, C Carpio, C Sobrino, V Collada, J Domínguez-Ortega, A Herrero, S Quirce, R Álvarez-Sala","doi":"10.18176/jiaci.0920","DOIUrl":"10.18176/jiaci.0920","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"60-61"},"PeriodicalIF":7.2,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9689302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exhaustive Diagnosis of Heat Urticaria in a Regular Clinical Practice: Report of 2 Cases. 常规临床实践中热性荨麻疹的详尽诊断:2 个病例的报告。
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-05-23 DOI: 10.18176/jiaci.0915
P Andrade Garbán, A Rosado, J Macías Iglesias, M Goyanes Malumbres, M Moro Moro
{"title":"Exhaustive Diagnosis of Heat Urticaria in a Regular Clinical Practice: Report of 2 Cases.","authors":"P Andrade Garbán, A Rosado, J Macías Iglesias, M Goyanes Malumbres, M Moro Moro","doi":"10.18176/jiaci.0915","DOIUrl":"10.18176/jiaci.0915","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"56-57"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9558371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Tailored 7- to 10-Day Lenalidomide Desensitization Protocol. 量身定制的 7-10 天来那度胺脱敏方案
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-06-01 DOI: 10.18176/jiaci.0914
K Pose, E Narváez-Fernández, A López de la Guía, L De Las Vecillas, J Domínguez-Ortega, M Lluch-Bernal, A Fiandor, R Cabañas
{"title":"A Tailored 7- to 10-Day Lenalidomide Desensitization Protocol.","authors":"K Pose, E Narváez-Fernández, A López de la Guía, L De Las Vecillas, J Domínguez-Ortega, M Lluch-Bernal, A Fiandor, R Cabañas","doi":"10.18176/jiaci.0914","DOIUrl":"10.18176/jiaci.0914","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"49-50"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9559795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Life-threatening Idiopathic Nonhistaminergic Acquired Angioedema With Response to Lanadelumab. 危及生命的特发性非组织胺能获得性血管性水肿对 Lanadelumab 有反应。
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-07-05 DOI: 10.18176/jiaci.0926
P Gamboa, C Galán, A Arrien, A Segurola, I Jáuregui
{"title":"Life-threatening Idiopathic Nonhistaminergic Acquired Angioedema With Response to Lanadelumab.","authors":"P Gamboa, C Galán, A Arrien, A Segurola, I Jáuregui","doi":"10.18176/jiaci.0926","DOIUrl":"10.18176/jiaci.0926","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"68-70"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9742357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the ERS/ATS 2022 Guidelines for Interpretation of Lung Function Test Results When Assessing the Response to Biologics in Asthma. ERS/ATS 2021肺功能解释指南对评估哮喘生物制剂反应的影响。
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-09-20 DOI: 10.18176/jiaci.0943
L Pérez de Llano, M C Muñiz Fernández, I Dávila
{"title":"Impact of the ERS/ATS 2022 Guidelines for Interpretation of Lung Function Test Results When Assessing the Response to Biologics in Asthma.","authors":"L Pérez de Llano, M C Muñiz Fernández, I Dávila","doi":"10.18176/jiaci.0943","DOIUrl":"10.18176/jiaci.0943","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"73-74"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41155699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is Pru p 7 (Peamaclein) Sensitization a Predominant Cause of Cypress Pollen-Associated Peach Allergy in Spain? 在西班牙,Pru p 7(豌豆黄)致敏是导致柏树花粉相关桃过敏症的主要原因吗?
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-06-21 DOI: 10.18176/jiaci.0922
D Betancor, S Fernandez-Bravo, E Nuñez-Borque, B Gonzalez-Cano, V Esteban, C Pastor-Vargas, J Cuesta-Herranz
{"title":"Is Pru p 7 (Peamaclein) Sensitization a Predominant Cause of Cypress Pollen-Associated Peach Allergy in Spain?","authors":"D Betancor, S Fernandez-Bravo, E Nuñez-Borque, B Gonzalez-Cano, V Esteban, C Pastor-Vargas, J Cuesta-Herranz","doi":"10.18176/jiaci.0922","DOIUrl":"10.18176/jiaci.0922","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"53-55"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9686679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Positioning of Tezepelumab in Severe Asthma. 特zepelumab在严重哮喘中的定位。
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-10-09 DOI: 10.18176/jiaci.0949
J C Miralles-López, D Antolín-Amérigo, I García-Moguel, J Domínguez-Ortega, J Delgado-Romero, S Quirce

Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress the complex type 2 (T2) inflammatory cascade. Biologics targeting more upstream molecules in the pathophysiological pathway of asthma could treat asthma more effectively. Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). It is the first marketed biologic against an epithelial cell-derived cytokine, preventing binding of TSLP to its receptor and reducing the immune stimuli that TSLP can trigger in different asthma endotypes. Tezepelumab reduces downstream biomarkers of inflammation, such as blood and airway eosinophils, FeNO, IgE, IL-5, and IL-13. Tezepelumab provides a clinical benefit in severe asthma, reducing the annualized asthma exacerbation rate in patients with either high or low levels of biomarkers of T2 inflammation, although the effect is greater among those with high levels. The drug has been shown to improve asthma control, quality of life, and lung function and reduce airway hyperresponsiveness. Therefore, tezepelumab can be used across the spectrum of patients with severe uncontrolled asthma, especially in T2-high patients. This review includes a positioning statement by the authors, all of whom are members of the SEAIC Asthma Committee.

哮喘是最常见的慢性疾病之一,严重哮喘的患病率估计占哮喘总人口的3-10%。需要额外的生物治疗,在严重的不受控制的哮喘中具有高效性。目前可用的药物抑制一种或两种特异性细胞因子或IgE抗体,因此仅部分抑制复杂的2型炎症级联反应。靶向哮喘病理生理途径中更多上游分子的生物制品可以更有效地治疗哮喘。Tezepelumab是一种针对细胞因子胸腺基质淋巴细胞生成素(TSLP)的人单克隆抗体免疫球蛋白G2λ(IgG2λ)。它是第一种针对上皮衍生细胞因子的上市生物制剂,可以防止TSLP与其受体的结合,并减少TSLP在不同类型哮喘中可能产生的免疫刺激。Tezepelumab可降低炎症的下游生物标志物,如血液和气道嗜酸性粒细胞、FeNO、IgE、IL-5和IL-13。Tezepelumab在严重哮喘中具有临床益处,降低了T2炎症生物标志物高或低水平患者的哮喘年加重率,尽管在高水平患者中效果更大,而且它已被证明可以改善哮喘控制、生活质量和肺功能,并降低气道高反应性。因此,特zepelumab可用于所有严重未控制哮喘患者,尤其是T2高患者。这篇综述包括作者、SEAIC哮喘委员会成员的定位声明。
{"title":"Positioning of Tezepelumab in Severe Asthma.","authors":"J C Miralles-López, D Antolín-Amérigo, I García-Moguel, J Domínguez-Ortega, J Delgado-Romero, S Quirce","doi":"10.18176/jiaci.0949","DOIUrl":"10.18176/jiaci.0949","url":null,"abstract":"<p><p>Asthma is one of the most common chronic diseases and is estimated to be severe in 3%-10% of affected patients. There is a need for additional biologic treatments that are highly efficacious across the spectrum of severe uncontrolled asthma. Currently available drugs inhibit 1 or 2 specific cytokines or IgE antibodies and thus only partially suppress the complex type 2 (T2) inflammatory cascade. Biologics targeting more upstream molecules in the pathophysiological pathway of asthma could treat asthma more effectively. Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). It is the first marketed biologic against an epithelial cell-derived cytokine, preventing binding of TSLP to its receptor and reducing the immune stimuli that TSLP can trigger in different asthma endotypes. Tezepelumab reduces downstream biomarkers of inflammation, such as blood and airway eosinophils, FeNO, IgE, IL-5, and IL-13. Tezepelumab provides a clinical benefit in severe asthma, reducing the annualized asthma exacerbation rate in patients with either high or low levels of biomarkers of T2 inflammation, although the effect is greater among those with high levels. The drug has been shown to improve asthma control, quality of life, and lung function and reduce airway hyperresponsiveness. Therefore, tezepelumab can be used across the spectrum of patients with severe uncontrolled asthma, especially in T2-high patients. This review includes a positioning statement by the authors, all of whom are members of the SEAIC Asthma Committee.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"1-11"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41172065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From MASK-air and SILAM to CATALYSE (Climate Action To Advance HeaLthY Societies in Europe). 从 MASK-air 和 SILAM 到 CATALYSE(欧洲促进健康社会气候行动)。
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-07-26 DOI: 10.18176/jiaci.0923
B Sousa-Pinto, Y Palamarchuk, L Leemann, S Jankin, X Basagaña, J Ballester, A Bedbrook, W Czarlewski, R Almeida, T Haahtela, H Haveri, M Prass, T Henriques, R J Vieira, L Klimek, M Ollert, M H Shamji, M Jutel, S Del Giacco, M J Torres, T Zuberbier, J A Fonseca, M Sofiev, J M Anto, J Bousquet

Plant species vary under different climatic conditions and the distribution of pollen in the air. Trends in pollen distribution can be used to assess the impact of climate change on public health. In 2015, the Mobile Airways Sentinel networK for rhinitis and asthma (MASK-air®) was launched as a project of the European Innovation Partnership on Active and Healthy Ageing (EIP-on-AHA, DG Santé and DG CONNECT). This project aimed to develop a warning system to inform patients about the onset of the pollen season, namely, the System for Integrated modeLling of Atmospheric coMposition (SILAM). A global-to-meso-scale dispersion model was developed by the Finnish Meteorological Institute (FMI). It provides quantitative information on atmospheric pollution of anthropogenic and natural origins, particularly on allergenic pollens. Impact of Air Pollution on Asthma and Rhinitis (POLLAR, EIT Health) has combined MASK-air clinical data with SILAM forecasts. A new Horizon Europe grant (Climate Action to Advance HeaLthY Societies in Europe [CATALYSE]; grant agreement number 101057131), which came into force in September 2022, aims to improve our understanding of climate change and help us find ways to counteractit. One objective of this project is to develop early warning systems and predictive models to improve the effectiveness of strategies for adapting to climate change. One of the warning systems is focused on allergic rhinitis (CATALYSE Task 3.2), with a collaboration between the FMI (Finland), Porto University (Portugal), MASK-air SAS (France), ISGlobal (Spain), Hertie School (Germany), and the University of Zurich (Switzerland). It is to be implemented with the support of the European Academy of Allergy and Clinical Immunology. This paper reports the planning of CATALYSE Task 3.2.

在不同的气候条件下,植物种类会有所不同,空气中的花粉分布也不尽相同。花粉分布趋势可用于评估气候变化对公众健康的影响。2015 年,鼻炎和哮喘移动空气哨兵网络(MASK-air®)作为欧洲积极健康老龄化创新伙伴关系(EIP-on-AHA、卫生总局和 CONNECT 总局)的一个项目启动。该项目旨在开发一种预警系统,即大气协同定位综合模式系统(SILAM),以便在花粉季节来临时通知患者。芬兰气象研究所(FMI)开发了一个全球到中尺度的扩散模型。它提供了有关人为和自然大气污染的定量信息,特别是有关过敏原花粉的信息。空气污染对哮喘和鼻炎的影响(POLLAR,EIT Health)将 MASK 空气临床数据与 SILAM 预测相结合。一项新的欧洲地平线补助金(促进欧洲健康社会的气候行动[CATALYSE];补助金协议编号 101057131)于 2022 年 9 月生效,旨在提高我们对气候变化的认识,帮助我们找到应对气候变化的方法。该项目的目标之一是开发早期预警系统和预测模型,以提高适应气候变化战略的有效性。其中一个预警系统的重点是过敏性鼻炎(CATALYSE 任务 3.2),合作方包括 FMI(芬兰)、波尔图大学(葡萄牙)、MASK-air SAS(法国)、ISGlobal(西班牙)、Hertie 学院(德国)和苏黎世大学(瑞士)。该项目将在欧洲过敏与临床免疫学学会的支持下实施。本文报告了 CATALYSE 任务 3.2 的规划情况。
{"title":"From MASK-air and SILAM to CATALYSE (Climate Action To Advance HeaLthY Societies in Europe).","authors":"B Sousa-Pinto, Y Palamarchuk, L Leemann, S Jankin, X Basagaña, J Ballester, A Bedbrook, W Czarlewski, R Almeida, T Haahtela, H Haveri, M Prass, T Henriques, R J Vieira, L Klimek, M Ollert, M H Shamji, M Jutel, S Del Giacco, M J Torres, T Zuberbier, J A Fonseca, M Sofiev, J M Anto, J Bousquet","doi":"10.18176/jiaci.0923","DOIUrl":"10.18176/jiaci.0923","url":null,"abstract":"<p><p>Plant species vary under different climatic conditions and the distribution of pollen in the air. Trends in pollen distribution can be used to assess the impact of climate change on public health. In 2015, the Mobile Airways Sentinel networK for rhinitis and asthma (MASK-air®) was launched as a project of the European Innovation Partnership on Active and Healthy Ageing (EIP-on-AHA, DG Santé and DG CONNECT). This project aimed to develop a warning system to inform patients about the onset of the pollen season, namely, the System for Integrated modeLling of Atmospheric coMposition (SILAM). A global-to-meso-scale dispersion model was developed by the Finnish Meteorological Institute (FMI). It provides quantitative information on atmospheric pollution of anthropogenic and natural origins, particularly on allergenic pollens. Impact of Air Pollution on Asthma and Rhinitis (POLLAR, EIT Health) has combined MASK-air clinical data with SILAM forecasts. A new Horizon Europe grant (Climate Action to Advance HeaLthY Societies in Europe [CATALYSE]; grant agreement number 101057131), which came into force in September 2022, aims to improve our understanding of climate change and help us find ways to counteractit. One objective of this project is to develop early warning systems and predictive models to improve the effectiveness of strategies for adapting to climate change. One of the warning systems is focused on allergic rhinitis (CATALYSE Task 3.2), with a collaboration between the FMI (Finland), Porto University (Portugal), MASK-air SAS (France), ISGlobal (Spain), Hertie School (Germany), and the University of Zurich (Switzerland). It is to be implemented with the support of the European Academy of Allergy and Clinical Immunology. This paper reports the planning of CATALYSE Task 3.2.</p>","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"12-19"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9874300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ATAK Complex due to Amoxicillin: A Case Report. 阿莫西林引起的 ATAK 复合物:病例报告。
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-06-09 DOI: 10.18176/jiaci.0921
E Alarcón Gallardo, R Escudero Apesteguía, C Sanz Bescós
{"title":"ATAK Complex due to Amoxicillin: A Case Report.","authors":"E Alarcón Gallardo, R Escudero Apesteguía, C Sanz Bescós","doi":"10.18176/jiaci.0921","DOIUrl":"10.18176/jiaci.0921","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"62-64"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9950881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergy to Moth Plant (Araujia sericifera) and Passion Fruit. 对飞蛾草(Araujia sericifera)和百香果过敏。
IF 7.2 3区 医学 Q1 ALLERGY Pub Date : 2024-02-22 Epub Date: 2023-06-01 DOI: 10.18176/jiaci.0916
M A Díaz-Palacios, R López-Salgueiro, N Catalán-Cáceres, E Ibáñez-Echevarría, R Alamar-Martínez, B Bartolomé
{"title":"Allergy to Moth Plant (Araujia sericifera) and Passion Fruit.","authors":"M A Díaz-Palacios, R López-Salgueiro, N Catalán-Cáceres, E Ibáñez-Echevarría, R Alamar-Martínez, B Bartolomé","doi":"10.18176/jiaci.0916","DOIUrl":"10.18176/jiaci.0916","url":null,"abstract":"","PeriodicalId":50173,"journal":{"name":"Journal of Investigational Allergology and Clinical Immunology","volume":" ","pages":"58-59"},"PeriodicalIF":7.2,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9559794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Investigational Allergology and Clinical Immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1